Strikingly, the resistance of p53-deficient cancer cells to these treatments could be overcome by facilitating Ca2+ transfer between the ER and the mitochondria via overexpression of SERCA or of the mitochondrial Ca2+ uniporter (MCU). Here, TP53 is linked to cancer.